INTELLIPHARMACEUTICS INTERNATIONAL INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.08 CAD | -.--% |
|
-11.11% | +6.67% |
Valuation
| Fiscal Period: Noviembre | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 29.32 | 3.256 | 3.325 | 2.914 | 3.753 | 2.467 |
| Enterprise Value (EV) 1 | 28.71 | -1.595 | 5.165 | 4.824 | 4.899 | 4.709 |
| P/E ratio | -2.96 x | -0.12 x | -0.4 x | -0.86 x | -0.65 x | -0.85 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5.33 x | 1.9 x | 0.96 x | 2.08 x | - | 37.5 x |
| EV / Revenue | 5.22 x | -0.93 x | 1.48 x | 3.44 x | - | 71.6 x |
| EV / EBITDA | -3.7 x | 0.13 x | -0.7 x | -1.13 x | -1.24 x | -1.78 x |
| EV / FCF | -6.57 x | 0.22 x | -3.2 x | -5.6 x | -4.87 x | -9.66 x |
| FCF Yield | -15.2% | 457% | -31.2% | -17.9% | -20.6% | -10.4% |
| Price to Book | 75.9 x | 1.51 x | -0.9 x | -0.46 x | -0.46 x | -0.23 x |
| Nbr of stocks (in thousands) | 3,470 | 9,622 | 22,086 | 23,678 | 33,093 | 33,093 |
| Reference price 2 | 8.449 | 0.3384 | 0.1506 | 0.1231 | 0.1134 | 0.0745 |
| Announcement Date | 2/16/18 | 2/22/19 | 2/28/20 | 3/1/21 | 2/28/22 | 6/5/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Noviembre | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5.504 | 1.713 | 3.481 | 1.402 | - | 0.0657 |
| EBITDA 1 | -7.759 | -12.73 | -7.334 | -4.266 | -3.948 | -2.645 |
| EBIT 1 | -8.266 | -13.33 | -7.835 | -4.678 | -4.208 | -2.851 |
| Operating Margin | -150.17% | -778.07% | -225.11% | -333.8% | - | -4,336.82% |
| Earnings before Tax (EBT) 1 | -8.857 | -13.75 | -8.09 | -3.358 | -5.259 | -2.887 |
| Net income 1 | -8.857 | -13.75 | -8.085 | -3.391 | -5.145 | -2.892 |
| Net margin | -160.91% | -802.66% | -232.28% | -241.95% | - | -4,400.55% |
| EPS 2 | -2.856 | -2.887 | -0.3746 | -0.1439 | -0.1748 | -0.0874 |
| Free Cash Flow 1 | -4.373 | -7.289 | -1.612 | -0.8614 | -1.007 | -0.4877 |
| FCF margin | -79.45% | -425.61% | -46.31% | -61.46% | - | -741.93% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/16/18 | 2/22/19 | 2/28/20 | 3/1/21 | 2/28/22 | 6/5/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: November | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 1.84 | 1.91 | 1.15 | 2.24 |
| Net Cash position 1 | 0.61 | 4.85 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.2509 x | -0.4479 x | -0.2901 x | -0.8476 x |
| Free Cash Flow 1 | -4.37 | -7.29 | -1.61 | -0.86 | -1.01 | -0.49 |
| ROE (net income / shareholders' equity) | -1,179% | -613% | -3,943% | 67.8% | 71.1% | 30.9% |
| ROA (Net income/ Total Assets) | -67.2% | -88.3% | -64.1% | -81.4% | -95.9% | -101% |
| Assets 1 | 13.18 | 15.57 | 12.61 | 4.166 | 5.364 | 2.864 |
| Book Value Per Share 2 | 0.1100 | 0.2200 | -0.1700 | -0.2700 | -0.2500 | -0.3200 |
| Cash Flow per Share 2 | 0.5500 | 0.3600 | 0 | 0.0100 | 0.0200 | 0 |
| Capex 1 | 1.82 | 0.1 | 0.01 | 0 | - | - |
| Capex / Sales | 33.13% | 5.91% | 0.42% | 0.28% | - | - |
| Announcement Date | 2/16/18 | 2/22/19 | 2/28/20 | 3/1/21 | 2/28/22 | 6/5/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +6.67% | 1.93M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- IPCI.H Stock
- Financials Intellipharmaceutics International Inc.
